A Randomized, Open-label, Multi-center Phase II Study to Compare AUY922 With Docetaxel or Irinotecan in Adult Patients With Advanced Gastric Cancer, Who Have Progressed After One Line of Chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Luminespib (Primary) ; Docetaxel; Irinotecan
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 27 Apr 2016 Status changed from discontinued to completed.
- 05 Apr 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 06 Jun 2012 New source identified and integrated (German Clinical Trials Register; DRKS00003744).